Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples

Bioinks and biofabrication techniques for biosensors development: A review

3D bioprinting technologies and bioink development are enabling significant advances in miniaturized and integrated biosensors. For example, bioreceptors can be immobilized within a porous 3D structure to significantly amplify the signal, while biocompatible and mechanically flexible systems uniquely enable wearable chem- and bio-sensors. This advancement is accelerating translation by enabling the production of high performance, reproducible, and flexible analytical devices. The formulation of the bioink plays a crucial role in determining the bio-functionality of the resulting printed structures, e.g., the porosity that allows the analyte to diffuse through the 3D structure, the affinity and avidity of the receptors, etc. This review explores the next generation of advanced bioinks for biosensor development and provides insights into the latest cutting-edge bioprinting technologies. The bioprinting methods available for biosensor fabrication including inkjet, extrusion, and laser-based bioprinting, are discussed. The advantages and limitations of each method are analysed, and recent advancements in bioprinting technologies are presented. The review then delves into the properties of advanced bioinks, such as biocompatibility, printability, stability, and applicability. Different types of advanced bioinks are explored, including multicomponent, stimuli-responsive, and conductive bioinks. Finally, the next generation of bioinks for biosensors is considered, identifying possible new opportunities and challenges. Overall, this literature review highlights the combined importance of bioink formulation and bioprinting methods for the development of high-performance analytical biosensors.

Enhancing Cervical Cancer Screening: Review of p16/Ki-67 Dual Staining as a Promising Triage Strategy

Cervical cancer, primarily caused by high-risk human papillomavirus (HR-HPV) types 16 and 18, is a major global health concern. Persistent HR-HPV infection can progress from reversible precancerous lesions to invasive cervical cancer, which is driven by the oncogenic activity of human papillomavirus (HPV) genes, particularly E6 and E7. Traditional screening methods, including cytology and HPV testing, have limited sensitivity and specificity. This review explores the application of p16/Ki-67 dual-staining cytology for cervical cancer screening. This advanced immunocytochemical method allows for simultaneously detecting p16 and Ki-67 proteins within cervical epithelial cells, offering a more specific approach for triaging HPV-positive women. Dual staining and traditional methods are compared, demonstrating their high sensitivity and negative predictive value but low specificity. The increased sensitivity of dual staining results in higher detection rates of CIN2+ lesions, which is crucial for preventing cervical cancer progression. However, its low specificity may lead to increased false-positive results and unnecessary biopsies. The implications of integrating dual staining into contemporary screening strategies, particularly considering the evolving landscape of HPV vaccination and changes in HPV genotype prevalence, are also discussed. New guidelines and further research are necessary to elucidate the long-term effects of integrating dual staining into screening protocols.